Which medications in the drug class PD-1/PD-L1 Inhibitors are used in the treatment of Hodgkin Lymphoma?

Updated: Sep 12, 2018
  • Author: Bradley W Lash, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

PD-1/PD-L1 Inhibitors

Immunotherapy is emerging for use in hematologic malignancies.

PD-1 and related target PD-ligand 1 (PD-L1) are expressed on the surface of activated T cells under normal conditions. PD-L1/PD-1 interaction inhibits immune activation and reduces T-cell cytotoxic activity when bound.

This negative feedback loop is essential for maintaining normal immune responses and limits T-cell activity to protect normal cells during chronic inflammation.

Nivolumab (Opdivo)

Monoclonal antibody which inhibits suppression of T-cells by blocking the interaction between programmed cell death-1 protein and its ligands. Nivolumab is indicated for the treatment of classical Hodgkin lymphoma in patients who have relapsed or shown progression after autologous hematopoietic stem cell transplantation (HSCT) and post transplantation brentuximab vedotin.

Pembrolizumab (Keytruda)

Monoclonal antibody to programmed cell death-1 protein (PD-1); blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. It is indicated for adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL) or who have relapsed after 3 or more prior lines of therapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!